Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2008 May 5.

Published in final edited form as: Toxicol Appl Pharmacol. 2005 Sep 1;207(2):147–159. doi: 10.1016/j.taap.2004.12.007

Fig. 1 — Expression and activity of rAS3MT in UROtsa/F35 cells. (a) RT-PCR analysis: (1) positive control (pLEGFP-N1/rAS3MT plasmid); (2) UROtsa cells; (3) UROtsa/F35 cells; (4) negative control. (b) Immunoblot analysis: (1) recombinant His-tagged rAS3MT (M_r~45 kDa); (2) UROtsa cells; (3) UROtsa/F35 cells expressing native rAS3MT (M_r~41 kDa). (c) TLC analysis of ⁷³As-metabolites in cell cultures exposed to carrier-free [⁷³As]iAs^III for 63 h: (1) UROtsa culture; (2) UROtsa/F35 culture.